Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT

Authors :: Kavita Raj
Dirk-Jan Eikema
Vipul Sheth
Linda Koster
Liesbeth C. de Wreede
Didier Blaise
Carmela Di Grazia
Yener Koc
Victoria Potter
Patrice Chevallier
Lucia Lopez- Corral
Depei Wu
Stephan Mielke
Johan Maertens
Ellen Meijer
Anne Huynh
Jakob Passweg
Thomas Luft
Jose Antonio Pérez-Simón
Fabio Ciceri
Agnieszka Piekarska
G. Hayri Ozsan
Nicolaus Kröger
Marie Robin
Ibrahim Yakoub-Agha
Source :: Blood Cancer Journal, Vol 12, Iss 9, Pp 1-10 (2022)
Publication Year :: 2022
Publisher :: Nature Publishing Group, 2022.
Abstract: Abstract Myelodysplastic syndromes (MDS) are the second common indication for an Allo-HCT. We compared the outcomes of 1414 matched sibling (MSD) with 415 haplo-identical donors (HD) transplanted with post-transplant cyclophosphamide (PTCy) as GVHD prophylaxis between 2014 and 2017. The median age at transplant with MSD was 58 and 61 years for HD. The median time to neutrophil engraftment was longer for HD being 20 vs 16 days for MSD (p

Subjects :: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282

Full Text Access

Tools